Jie Wang

Jie Wang

Auto-generated profile, based on publicly available information

Jie Wang

Department of Ophthalmology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2026 in Aging Cell
Verified
Journal Article
Open access
PDF file
JWJie Wang
Jie Wang
YSYuehui Su
Yuehui Su
CCChao Chen
Chao Chen
YLYueying Li
Yueying Li
JHJiajia Han
Jiajia Han
YPYing Peng
Ying Peng
Cell division inevitably shortens telomeric DNA owing to the end‐replication problem. Eukaryotic chromosomes possess specialized telomere structures to maintain genomic stability. In most proliferative cells, telomerase adds telomeric repeats during S‐phase. In differentiated cells where telomerase is silenced, telomeres shorten progressively, thereby compromising genomic integrity. Consequently, cancer cells universally activate alternative telomere maintenance mechanisms during malignant transformation: ~80% reactivate telomerase, while a portion of the rest rely on BIR (break‐induced replication)–mediated homologous recombination‐based ALT (alternative lengthening of telomeres). Although these mechanisms are stable once established, the initial determinants influencing a cancer cell's choice remain poorly understood. This review discusses recent molecular insights into how telomeric chromatin properties profoundly impact this choice. After briefly introducing telomere chromatin characteristics and key players in its maintenance and dynamics, we discuss the mechanisms by which cancer cells acquire distinct telomere replication capabilities. In particular, we present an in‐depth analysis linking telomere heterochromatin status to ALT. Furthermore, based on recent advances, we propose a coupled feedforward loop model explaining how the ALT state becomes “locked in” once initiated. Finally, we offer novel perspectives on rational, telomere‐centric therapeutic interventions for ALT‐positive cancers, focusing on strategies designed to disrupt such feedforward loops by manipulating telomeric chromatin structure.